SCHEMBL17591502

SCHEMBL17591502

Cc1ccccc1/N=C\C=N/N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.50
HPGD P15428 2/20 0.50
CYP2C9 P11712 1/20 0.50
MAPT P10636 6/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
RECQL P46063 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.42
MPI P34949 1/20 0.42
HTT P42858 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239326 0.89 CYP2C9 (0.59) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL29472028 0.89 CYP2C9 (0.59) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL239325 0.89 CYP2C9 (0.59) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL16234584 0.83 CYP2C9 (0.53) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL14404845 0.79 LMNA (0.50) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL17591505 0.77 MEN1 (0.36) CYP2C9ALDH1A1TDP1SIGMAR1TSHR
SCHEMBL12332461 0.77 CYP2C9 (0.52) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL7091919 0.77 CYP2C9 (0.52) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL21728463 0.77 CYP2C9 (0.52) LMNAHPGDCYP2C9MAPTALDH1A1
SCHEMBL17591503 0.76 DHODH (0.44) LMNAHPGDMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776430-B1 2- (1,2,3-TRIAZOL-2-YL) BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL) PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2016-03-16 EP disclosed